Alnylam Pharmaceuticals Inc

ALNY remains in a Stage 4 decline within a broader secular uptrend. The breakdown below major support and declining EMAs reinforces a medium-term bearish bias. Short-term conditions are extended below EMAs and extreme oversold, warranting patience. Execution should be deferred (Trim) into a corrective relief rally or pullback into the 9/21 EMA zone, as the active Support Failure pattern warns of further downside without confirmation.

• ↑Q1 net revenue exceeded $1B, up 121% YoY; TTR franchise $910M (+153%).
• ↑Pipeline set to expand from 25 to over 40 trials, including Down syndrome–associated Alzheimer’s.
• ↓Earnings yield is negative, highlighting overvaluation concerns.